- Home
- FMAC vs PLX Comparison
FMAC vs PLX Comparison
Compare FMAC & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMAC | PLX |
|---|---|---|
| Founded | 2025 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.2M | 182.9M |
| IPO Year | 2025 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FMAC | PLX |
|---|---|---|
| Price | $10.06 | $2.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.3K | ★ 622.4K |
| Earning Date | N/A | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.02 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.95 | $1.60 |
| 52 Week High | $10.09 | $3.19 |
Technical Indicators
Market Signals| Indicator | FMAC | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 59.49 |
| Support Level | $10.01 | $2.21 |
| Resistance Level | N/A | $2.82 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 57.14 | 66.81 |
Price Performance
Historical ComparisonAbout FMAC Future Money Acquisition Corporation Ordinary Shares
Future Money Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.